Pharma

Your Article Summary

See Latest Articles

BTG plc: Campath Meets Primary Endpoint in Phase III Combination Therapy Trial for Chronic Lymphocytic Leukemia
BTG, 09/25/09

BTG plc, the specialty pharmaceuticals company, notes announcement by Genzyme Corporation that its randomised Phase III clinical trial investigating Campath in combination with Fludara in relapsed or refractory chronic lymphocytic leukemia patients met its primary endpoint by demonstrating a significant improvement in progression free survival.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

 See all of Drug Trials